Ixabiso loKhuphiswano lweFactory Wholesale Organic Intermediate BMK Pmk Powder 1-Propanol, 2-Methyl-2-[ (phenylmethylene) Amino]- CAS 22563-90-2

"Umgangatho wokuqala, Ukunyaniseka njengesiseko, Uncedo olunyanisekileyo kunye nenzuzo efanayo" yimbono yethu, kumzamo wokudala ngokungaguqukiyo kwaye silandele ukugqwesa kweXabiso loKhuphiswano lweFactory Wholesale Organic Intermediate BMK Pmk Powder 1-Propanol, 2-Methyl-2- [(phenylmethylene) Amino]- I-CAS 22563-90-2, Umgangatho ophezulu uya kuba yinto ephambili yokuba lo mbutho uphume kwabanye abakhuphisana nabo.Ukubona kukukholelwa, ufuna ulwazi oluninzi?Ukuvavanywa nje kwizinto zayo!
"Umgangatho wokuqala, ukunyaniseka njengesiseko, uncedo olunyanisekileyo kunye nenzuzo efanayo" ngumbono wethu, kumzamo wokudala ngokungaguqukiyo kwaye silandele ukugqwesaAbaPhakathi bezoPhando baseTshayina kunye nabaPhakathi beAgrochemical, Ukufumana ulwazi oluthe kratya malunga nathi kunye nokubona zonke iimpahla zethu, nceda undwendwele iwebhusayithi yethu.Ukuze ufumane inkcazelo engakumbi nceda uzive ukhululekile ukusivumela ukuba sazi.Enkosi kakhulu kwaye ndinqwenela ukuba ishishini lakho lihlale lihle!

I-3′-Amino-2′-hydroxy-[1,1'-bipheny] -3-carboxylic acid isetyenziswa njengendawo ephakathi ye-Eltrombopag.
I-Eltrombopag, ephuhliswe yi-GlaxoSmithKline (GSK) e-UK kwaye kamva iphuhliswe ngokudibeneyo kunye ne-Novartis eSwitzerland, yeyokuqala kwaye ivunyiwe kuphela i-molecule encinci ye-non peptide TPO receptor agonist emhlabeni.I-Eltrombopag yavunywa yi-US FDA kwi-2008 yonyango lwe-idiopathic thrombocytopenic purpura (ITP), kunye ne-2014 yonyango lwe-anemia ye-aplastic enzima (AA).Ikwalichiza lokuqala elavunywa yi-US FDA kunyango lwe-AA kwiminyaka engama-30 yakutsha nje.
NgoDisemba 2012, i-US FDA ivume i-Eltrombopag yonyango lwe-thrombocytopenia kwizigulane ezine-hepatitis C engapheliyo (CHC), ukwenzela ukuba izigulane ze-hepatitis C ezine-prognosis embi ngenxa yokubala kweplatelet ephantsi inokuqala kwaye igcine unyango oluqhelekileyo lwe-interferon kwizifo zesibindi.NgoFebruwari3, 2014, i-GlaxoSmithKline yabhengeza ukuba i-FDA inike isiqinisekiso sonyango lwe-Eltrombopag kunyango lwe-hemopenia kwizigulane ezine-chemicalbook aplastic anemia (SAA) ezinzima ezingazange ziphendule ngokupheleleyo kwi-immunotherapy.Ngo-Agasti 24, i-2015, i-US FDA ivume i-Eltrombopag yonyango lwe-thrombocytopenia kubantu abadala kunye nabantwana abaneminyaka eyi-1 kunye nangaphezulu kunye ne-immune immune thrombocytopenia (ITP) abangenayo impendulo eyaneleyo kwi-corticosteroids, i-immunoglobulins okanye i-splenectomy.NgoJanuwari4, 2018, i-Eltrombopag yavunywa ukuba ibhalwe e-China kunyango lwe-immune immune thrombocytopenia (ITP).

"Umgangatho wokuqala, Ukunyaniseka njengesiseko, Uncedo olunyanisekileyo kunye nenzuzo efanayo" yimbono yethu, kumzamo wokudala ngokungaguqukiyo kwaye silandele ukugqwesa kweXabiso loKhuphiswano lweFactory Wholesale Organic Intermediate BMK Pmk Powder 1-Propanol, 2-Methyl-2- [(phenylmethylene) Amino]- I-CAS 22563-90-2, Umgangatho ophezulu uya kuba yinto ephambili yokuba lo mbutho uphume kwabanye abakhuphisana nabo.Ukubona kukukholelwa, ufuna ulwazi oluninzi?Ukuvavanywa nje kwizinto zayo!
Ixabiso loKhuphiswano lweAbaPhakathi bezoPhando baseTshayina kunye nabaPhakathi beAgrochemical, Ukufumana ulwazi oluthe kratya malunga nathi kunye nokubona zonke iimpahla zethu, nceda undwendwele iwebhusayithi yethu.Ukuze ufumane inkcazelo engakumbi nceda uzive ukhululekile ukusivumela ukuba sazi.Enkosi kakhulu kwaye ndinqwenela ukuba ishishini lakho lihlale lihle!